RVTY
Revvity, Inc. NYSE Listed Jul 6, 1965$98.80
Mkt Cap $11.0B
52w Low $81.22
47.4% of range
52w High $118.30
50d MA $89.97
200d MA $94.35
P/E (TTM)
41.7x
EV/EBITDA
20.5x
P/B
1.4x
Debt/Equity
0.5x
ROE
3.3%
P/FCF
21.6x
RSI (14)
—
ATR (14)
—
Beta
1.13
50d MA
$89.97
200d MA
$94.35
Avg Volume
1.2M
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
77 4th Avenue · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | TNS | 1.02 | 1.06 | +3.9% | 92.30 | +1.3% | +7.4% | +7.1% | — | — | — | — |
| Feb 2, 2026 | TNS | 1.57 | 1.70 | +8.3% | 107.09 | +1.7% | -5.6% | -5.6% | -3.0% | -7.1% | -5.1% | — |
| Oct 27, 2025 | TNS | 1.14 | 1.18 | +3.5% | 97.16 | +1.2% | -0.7% | -0.7% | -1.9% | -6.3% | -3.7% | — |
| Jul 28, 2025 | TNS | 1.14 | 1.18 | +3.5% | 95.04 | -0.2% | -0.6% | -0.6% | -4.4% | -7.5% | -7.2% | — |
| Apr 28, 2025 | TNS | 0.96 | 1.01 | +5.2% | 95.06 | -0.1% | -0.4% | -0.4% | -1.7% | -2.3% | -1.1% | — |
| Jan 31, 2025 | TNS | 1.37 | 1.42 | +3.6% | 126.13 | -0.3% | -1.9% | -1.9% | -2.4% | -3.0% | -5.5% | — |
| Nov 4, 2024 | TNS | 1.13 | 1.28 | +13.3% | 124.82 | -1.2% | +0.9% | +0.9% | +0.0% | -0.7% | -1.9% | — |
| Jul 29, 2024 | TNS | 1.12 | 1.22 | +8.9% | 125.59 | +0.3% | +1.3% | +1.3% | +0.0% | -0.4% | -1.8% | — |
| Apr 29, 2024 | TNS | 0.94 | 0.98 | +3.9% | 105.02 | -0.7% | -2.4% | -2.4% | -2.3% | -3.8% | -4.2% | — |
| Feb 1, 2024 | TNS | 1.15 | 1.25 | +8.7% | 109.26 | -0.4% | -3.3% | -3.3% | -4.9% | -4.6% | -5.8% | — |
| Oct 30, 2023 | TNS | 1.19 | 1.18 | -0.8% | 82.08 | +0.5% | +0.9% | +0.9% | +0.6% | +2.3% | +7.4% | — |
| Aug 1, 2023 | TNS | 1.18 | 1.21 | +2.5% | 122.63 | -1.4% | +2.0% | +2.0% | +0.4% | +0.5% | +0.1% | — |
| May 11, 2023 | BMO | 1.06 | 1.01 | -4.7% | 118.37 | -0.8% | -1.7% | -1.7% | -2.6% | -3.5% | -2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Barclays | Downgrade | Overweight → Equal Weight | — | $92.64 | $92.50 | -0.2% | +0.9% | +0.3% | -3.4% | +1.4% | +0.4% |
| Apr 14 | Goldman Sachs | Maintains | Neutral → Neutral | — | $92.64 | $92.50 | -0.2% | +0.9% | +0.3% | -3.4% | +1.4% | +0.4% |
| Mar 31 | JP Morgan | Maintains | Neutral → Neutral | — | $84.78 | $86.20 | +1.7% | +3.3% | +3.7% | +4.9% | +4.2% | +3.6% |
| Feb 3 | JP Morgan | Maintains | Neutral → Neutral | — | $107.09 | $108.91 | +1.7% | -5.6% | -3.0% | -7.1% | -5.1% | -4.0% |
| Feb 3 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $107.09 | $108.91 | +1.7% | -5.6% | -3.0% | -7.1% | -5.1% | -4.0% |
| Feb 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $107.09 | $108.91 | +1.7% | -5.6% | -3.0% | -7.1% | -5.1% | -4.0% |
| Feb 3 | Jefferies | Maintains | Hold → Hold | — | $107.09 | $108.91 | +1.7% | -5.6% | -3.0% | -7.1% | -5.1% | -4.0% |
| Feb 3 | Barclays | Maintains | Overweight → Overweight | — | $107.09 | $108.91 | +1.7% | -5.6% | -3.0% | -7.1% | -5.1% | -4.0% |
| Feb 3 | TD Cowen | Maintains | Buy → Buy | — | $107.09 | $108.91 | +1.7% | -5.6% | -3.0% | -7.1% | -5.1% | -4.0% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $100.49 | $100.03 | -0.5% | -1.4% | -4.2% | -3.7% | -4.2% | -4.2% |
| Dec 15 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $100.49 | $100.03 | -0.5% | -1.4% | -4.2% | -3.7% | -4.2% | -4.2% |
| Oct 28 | Barclays | Maintains | Overweight → Overweight | — | $97.16 | $98.33 | +1.2% | -0.7% | -1.9% | -6.3% | -3.7% | -4.3% |
| Oct 28 | Baird | Maintains | Outperform → Outperform | — | $97.16 | $98.33 | +1.2% | -0.7% | -1.9% | -6.3% | -3.7% | -4.3% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $93.38 | $93.80 | +0.4% | -2.3% | -1.7% | -1.8% | -5.5% | -2.6% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $91.76 | $90.54 | -1.3% | -0.3% | +2.5% | +1.8% | -0.6% | +0.0% |
| Sep 22 | BofA Securities | Maintains | Buy → Buy | — | $86.72 | $85.93 | -0.9% | -0.5% | -1.2% | -2.6% | -4.2% | -3.1% |
| Jul 29 | Raymond James | Maintains | Outperform → Outperform | — | $95.04 | $94.84 | -0.2% | -0.6% | -4.4% | -7.5% | -7.2% | -7.1% |
| Jul 29 | Stifel | Maintains | Hold → Hold | — | $95.04 | $94.84 | -0.2% | -0.6% | -4.4% | -7.5% | -7.2% | -7.1% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $98.71 | $98.83 | +0.1% | +2.0% | +1.4% | +3.7% | +2.8% | -0.2% |
| Jun 26 | BofA Securities | Maintains | Buy → Buy | — | $97.70 | $98.18 | +0.5% | +1.1% | +0.1% | -1.0% | +1.4% | +3.3% |
| May 1 | UBS | Upgrade | Neutral → Buy | — | $93.43 | $94.89 | +1.6% | -0.6% | +0.6% | -0.6% | -3.2% | -2.0% |
| Apr 29 | JP Morgan | Maintains | Neutral → Neutral | — | $95.06 | $94.92 | -0.1% | -0.4% | -1.7% | -2.3% | -1.1% | -2.3% |
| Apr 29 | Raymond James | Maintains | Outperform → Outperform | — | $95.06 | $94.92 | -0.1% | -0.4% | -1.7% | -2.3% | -1.1% | -2.3% |
| Apr 29 | Baird | Maintains | Outperform → Outperform | — | $95.06 | $94.92 | -0.1% | -0.4% | -1.7% | -2.3% | -1.1% | -2.3% |
| Apr 29 | Goldman Sachs | Maintains | Buy → Buy | — | $95.06 | $94.92 | -0.1% | -0.4% | -1.7% | -2.3% | -1.1% | -2.3% |
| Apr 21 | Baird | Maintains | Outperform → Outperform | — | $91.82 | $90.88 | -1.0% | -2.2% | +0.6% | +2.0% | +3.6% | +2.7% |
| Apr 17 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $93.75 | $93.25 | -0.5% | -2.1% | -4.2% | -1.5% | -0.1% | +1.5% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $101.34 | $99.00 | -2.3% | -8.2% | -6.4% | -3.7% | -5.7% | -7.5% |
| Feb 3 | Barclays | Maintains | Overweight → Overweight | — | $126.13 | $125.74 | -0.3% | -1.9% | -2.4% | -3.0% | -5.5% | -5.8% |
| Feb 3 | Raymond James | Maintains | Outperform → Outperform | — | $126.13 | $125.74 | -0.3% | -1.9% | -2.4% | -3.0% | -5.5% | -5.8% |
| Feb 3 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $126.13 | $125.74 | -0.3% | -1.9% | -2.4% | -3.0% | -5.5% | -5.8% |
| Jan 21 | Raymond James | Maintains | Outperform → Outperform | — | $118.39 | $119.02 | +0.5% | +4.7% | +3.7% | +3.9% | +4.0% | +4.8% |
| Dec 13 | BofA Securities | Upgrade | Neutral → Buy | — | $116.01 | $116.71 | +0.6% | -0.1% | -0.7% | -1.1% | -5.9% | -4.7% |
| Nov 25 | Barclays | Maintains | Overweight → Overweight | — | $112.03 | $113.00 | +0.9% | +2.3% | +2.7% | +3.7% | +3.7% | +4.2% |
| Nov 5 | TD Cowen | Maintains | Buy → Buy | — | $124.82 | $123.29 | -1.2% | +0.9% | +0.0% | -0.7% | -1.9% | -3.3% |
| Nov 5 | Baird | Maintains | Outperform → Outperform | — | $124.82 | $123.29 | -1.2% | +0.9% | +0.0% | -0.7% | -1.9% | -3.3% |
| Nov 5 | Raymond James | Maintains | Outperform → Outperform | — | $124.82 | $123.29 | -1.2% | +0.9% | +0.0% | -0.7% | -1.9% | -3.3% |
| Nov 5 | Bernstein | Maintains | Outperform → Outperform | — | $124.82 | $123.29 | -1.2% | +0.9% | +0.0% | -0.7% | -1.9% | -3.3% |
| Oct 17 | Leerink Partners | Maintains | Outperform → Outperform | — | $120.18 | $121.70 | +1.3% | -0.9% | -0.4% | -0.8% | -1.2% | -1.4% |
| Oct 15 | Barclays | Upgrade | Equal Weight → Overweight | — | $122.91 | $124.61 | +1.4% | +1.2% | -2.2% | -3.1% | -2.6% | -3.0% |
| Jul 30 | Citigroup | Maintains | Buy → Buy | — | $125.59 | $126.02 | +0.3% | +1.3% | +0.0% | -0.4% | -1.8% | -4.3% |
| Jul 30 | JP Morgan | Maintains | Neutral → Neutral | — | $125.59 | $126.02 | +0.3% | +1.3% | +0.0% | -0.4% | -1.8% | -4.3% |
| Jul 30 | BofA Securities | Maintains | Neutral → Neutral | — | $125.59 | $126.02 | +0.3% | +1.3% | +0.0% | -0.4% | -1.8% | -4.3% |
| Jul 30 | TD Cowen | Maintains | Buy → Buy | — | $125.59 | $126.02 | +0.3% | +1.3% | +0.0% | -0.4% | -1.8% | -4.3% |
| Jul 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $125.59 | $126.02 | +0.3% | +1.3% | +0.0% | -0.4% | -1.8% | -4.3% |
| Jul 29 | Jefferies | Maintains | Hold → Hold | — | $115.15 | $121.44 | +5.5% | +9.1% | +10.4% | +9.1% | +8.6% | +7.1% |
| Jun 28 | Barclays | Maintains | Equal Weight → Equal Weight | — | $105.71 | $105.62 | -0.1% | -0.8% | -2.6% | -3.5% | -3.0% | -2.0% |
| Apr 30 | TD Cowen | Maintains | Buy → Buy | — | $105.02 | $104.30 | -0.7% | -2.4% | -2.3% | -3.8% | -4.2% | -2.1% |
| Apr 30 | Baird | Maintains | Outperform → Outperform | — | $105.02 | $104.30 | -0.7% | -2.4% | -2.3% | -3.8% | -4.2% | -2.1% |
| Feb 2 | Stifel | Maintains | Hold → Hold | — | $109.26 | $108.79 | -0.4% | -3.3% | -4.9% | -4.6% | -5.8% | -5.5% |
No insider trades available.
8-K · 2.02
!! High
Revvity, Inc. -- 8-K 2.02: Earnings Results
Revvity reported Q1 2026 earnings on May 5, 2026, with results ending April 5, 2026, providing investors updated financial performance metrics for the quarter.
May 5
8-K
Revvity, Inc. -- 8-K Filing
Revvity reported Q4 2025 revenue of $772 million with 6% growth and adjusted EPS of $1.70, while initiating 2026 guidance to support investor forward planning.
Feb 2
Data updated apr 26, 2026 11:45pm
· Source: massive.com